Anatomic and Clinical Pathology; Hematology (Pathology); Molecular Genetic Pathology
I am a pathologist who specializes in molecular genetic pathology and hematopathology. I also have an interest in developing new genetic tests for leukemia and lymphoma.
My molecular pathology work involves looking at mutations in samples from patients with cancer to diagnose, monitor, and help guide their therapies. This information also helps ensure each patient’s treatment plan is personalized to their unique cancer. As part of the Hematopathology Service, I integrate clinical and genetic information with microscopic and flow cytometry evaluation of patient tissues to diagnose blood cancers such as leukemia and lymphoma.
My research is focused on identifying the genetic changes that drive leukemia and lymphoma to uncover prognostic and therapeutic markers. This work dovetails with my clinical test development role in the Diagnostic Molecular Pathology Service.
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Mark D. Ewalt discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at email@example.com.